Prescient Therapeutics Ltd.

Prescient Therapeutics Ltd. is a clinical-stage oncology company focused on developing personalized medicine approaches to cancer, including targeted therapies and advanced cell therapies. The company’s lead drug candidate, PTX-100, is a first-in-class compound designed to disrupt oncogenic Ras pathways by inhibiting key signaling circuits in cancer cells, with ongoing Phase 2a clinical development and significant regulatory recognition, including FDA Fast Track and Orphan Drug designations. Prescient Therapeutics also owns two proprietary cell therapy platforms—OmniCAR, a universal CAR-T platform, and CellPryme, which enhances CAR-T cell manufacturing and function—both aimed at overcoming limitations of current cell therapies. The company’s research is supported by collaborations with leading global institutions such as Yale, Penn, Oxford, and Moffitt. Headquartered in Melbourne, Australia, Prescient Therapeutics is listed on the CHI-X Market Australia – Limit Venue, where its shares are traded as part of the broader Australian equity market, contributing to innovation in biotechnology and oncology treatment.